EGFR and non-small cell lung carcinoma: The ALTER-L004 trial was a multicenter, phase 2 single-arm exploratory clinical trial strongly suggesting the efficacy and safety of anlotinib combined with icotinib in patients with EGFR-mutated advanced NSCLC.